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Oxacillinase-mediated resistance to
carbapenems in Klebsiella pneumoniae from
Lebanon
Acquired resistance to carbapenems is uncom-
mon in Enterobacteriaceae [1,2], although extended-
spectrum b-lactamase-mediated resistance in
these organisms is well established [3]. However,
b-lactamase-mediated resistance to carbapenems
has been reported in Klebsiella pneumoniae, result-
ing mostly from the expression of either clavul-
anic acid-susceptible class A KPC b-lactamases or
from clavulanic acid-resistant class B metallo-
b-lactamases. Both types of enzymes have been
reported in many geographical regions world-
wide, with predominant spread of KPC enzymes
being seen in the USA and the Middle East [2,4–
6]. Rare reports of other types of acquired carba-
penemases in Enterobacteriaceae have been made,
e.g. clavulanic acid-inhibited IMI-1 ⁄ 2-positive
Enterobacter sp., GES-5 in K. pneumoniae, OXA-23
in a Proteus mirabilis isolate, and OXA-48 in
K. pneumoniae and Escherichia coli from Turkey
[7–10]. This report is the fourth worldwide of a
carbapenem-resistant K. pneumoniae isolate pro-
ducing OXA-48 and the first in Lebanon.
A 7-year-old female child had a 3-year history
of urinary tract infection. A K. pneumoniae isolate
(Kp1) grew from a urine culture that was resistant
to amoxycillin, ticarcillin, piperacillin, cephalo-
thin, imipenem and ertapenem and was suscep-
tible to ceftazidime, cefotaxime, cefepime,
aminoglycosides, quinolones, trimethoprim–
sulphamethoxazole and tigecycline, based on
susceptibility testing performed by disk diffusion
and the Etest method (AB Biodisk, Solna, Sweden)
and interpreted according to CLSI guidelines [11].
Addition of clavulanic acid or tazobactam did not
modify the b-lactam susceptibility profile of the
isolate (Table 1). The patient was treated with oral
cefixime, and responded well.
A crude b-lactamase extract of that iso-
late showed significant carbapenem-hydrolyzing
activity, as measured spectrophotometrically
(24 lmol imipenem ⁄mg total protein) [4]. A
b-lactamase extract from this isolate subjected to
analytical analysis contained two b-lactamases
with pI values of 7.2 and 7.5 [6]. Plasmid analysis
revealed several plasmids (c. 150, 70, 5, 4.5, 4 and
2 kb), whereas only plasmids of 70 and 4.5 kb
were transferred to azide-resistant E. coli J53 via
conjugation [4]. Transconjugants showed signifi-
cantly reduced susceptibility to imipenem and
ertapenem (Table 1). PCR experiments were neg-
ative using primers for detecting genes encoding
the following b-lactamases: TEM, SHV, CTX-M,
GES, KPC, IMI, OXA-1 ⁄ 2 ⁄OXA-10 ⁄ 18, OXA-
23 ⁄ 58, IMP, VIM, SPM, GIM and SIM. The only
positive result was obtained using primers for
detection of a blaOXA-48-like gene that was located
on the 70-kb plasmid, as analyzed by Southern
hybridization using an intragenic probe for the
blaOXA-48-like gene (data not shown). The b-lac-
tamase gene was sequenced in its entirety, and
showed perfect identity with the blaOXA-48 gene.
In addition, the strain was compared to the
Turkish K. pneumoniae isolate 11978 [7] by
pulsed-field gel electrophoresis, [12], and the
strains did not have the same pulsed-field gel
electrophoresis pattern (data not shown).
This is the first evidence of b-lactamase-medi-
ated carbapenem resistance in Enterobacteriaceae in
Lebanon. Identification of OXA-48 outside Turkey
indicates that the spread of this novel and
powerful resistance determinant could be more
important than expected. One should be aware
now that carbapenemase-mediated resistance to
carbapenems in K. pneumoniae may be due to
KPC, VIM ⁄ IMP and OXA-48 in countries sur-
rounding the Mediterranean. The diversity of
carbapenemases in Enterobacteriaceae, their spread
and their possible role as a source of outbreaks are
Table 1. MICs of b-lactams for Klebsiella pneumoniae, its J53
Escherichia coli transconjugant and the J53 E. coli recipient
strain
Antimicrobial
agent
MIC (mg ⁄L)
Klebsiella
pneumoniae KP1
Escherichia
coli J53 transconjugant
Escherichia
coli J53
Amoxycillin >256 >256 4
Amoxycillin + CLA >256 >256 4
Ticarcillin >256 >256 2
Ticarcillin + CLA >256 >256 2
Piperacillin 96 64 1
Piperacillin + TZB 96 64 1
Cephalothin 32 8 4
Cefoxitin 8 2 2
Cefixime 0.25 0.12 0.12
Cefotaxime 1.5 0.25 0.06
Ceftazidime 0.75 0.75 0.06
Aztreonam 0.06 0.06 0.03
Cefepime 0.125 0.06 0.03
Imipenem 16–32 4 0.06
Ertapenem 16–32 4 0.06
Tigecycline 1.5 0.5 0.5
Colistin 0.38 0.38 0.38
CLA, clavulanic acid at a fixed concentration of 2 mg ⁄L; TZB, tazobactam at a fixed
concentration of 4 mg ⁄L.
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of concern in determining future therapeutic
options for infected patients in that region. In
addition, in all these cases, imipenem susceptibil-
ity, although reduced, may remain in the inter-
mediate range, leading to problems in detection.
Ertapenem seems to be more affected by the
expression of these enzymes in Enterobacteriaceae
and therefore appears to be a better indicator for
use in their detection.
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